Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Netarsudil After DWEK in Fuchs' Endothelial Dystrophy
NCT04752020Phase 1Completed
- Sponsor
- Massachusetts Eye and Ear
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of netarsudil in Fuchs endothelial dystrophy (FED) (2 arms), sponsored by Massachusetts Eye and Ear. Primary endpoints: Change in central corneal pachymetry over time at 12 months and Change in endothelial cell count over time at 12 months. Started Mar 2021; status: completed.
02
Drugs
netarsudil
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on NCT04752020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752020.